Foghorn Therapeutics Inc (FHTX) USD0.0001

Sell:$4.66Buy:$5.20$0.18 (3.64%)

Prices delayed by at least 15 minutes
Sell:$4.66
Buy:$5.20
Change:$0.18 (3.64%)
Prices delayed by at least 15 minutes
Sell:$4.66
Buy:$5.20
Change:$0.18 (3.64%)
Prices delayed by at least 15 minutes

Company Information

About this company

Foghorn Therapeutics Inc. is a clinical-stage, precision therapeutics biotechnology company. The Company is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.

Key people

Adrian Gottschalk
President, Chief Executive Officer, Director
Kristian F. Humer
Chief Financial Officer
Carlos Costa
Chief People Officer
Steven Bellon
Chief Scientific Officer
Michael LaCascia
Chief Legal Officer
Alfonso Quints-Cardama
Chief Medical Officer
Anna Rivkin
Chief Business Officer
Scott Biller
Independent Director
Douglas G. Cole
Independent Director
Stuart Duty
Independent Director
Niel J. Gallagher
Independent Director
Balkrishan Gill
Independent Director
Click to see more

Key facts

  • EPIC
    FHTX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US3441741077
  • Market cap
    $275.92m
  • Employees
    112
  • Shares in issue
    55.74m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.